Sea-Derived Compound Offers Hope Against Deadly Brain-Eating Amoebas

Brain-eating amoebas, such as Naegleria fowleri, cause rare but devastating infections with a fatality rate above 97%. Current treatments are often ineffective because the amoeba rapidly destroys brain tissue. Now, researchers have isolated a compound from marine sources that shows promise in stopping the disease. The discovery could lead to the first effective therapy for primary amoebic meningoencephalitis (PAM), a condition that has claimed lives worldwide, including recent cases in the United States and Asia. Scientists emphasize that while the compound has only been tested in laboratory models, it represents a critical step toward a targeted drug. The ocean, covering more than 70% of the planet, remains an underexplored reservoir of bioactive molecules. If further studies confirm its safety and efficacy, this marine-derived compound may transform a nearly hopeless diagnosis into a treatable one.